Xiaoyuan Xu

2.2k total citations · 1 hit paper
124 papers, 1.2k citations indexed

About

Xiaoyuan Xu is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Xiaoyuan Xu has authored 124 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Epidemiology, 78 papers in Hepatology and 13 papers in Infectious Diseases. Recurrent topics in Xiaoyuan Xu's work include Liver Disease Diagnosis and Treatment (60 papers), Hepatitis C virus research (52 papers) and Hepatitis B Virus Studies (52 papers). Xiaoyuan Xu is often cited by papers focused on Liver Disease Diagnosis and Treatment (60 papers), Hepatitis C virus research (52 papers) and Hepatitis B Virus Studies (52 papers). Xiaoyuan Xu collaborates with scholars based in China, United States and France. Xiaoyuan Xu's co-authors include Hui Zhuang, Jidong Jia, Wengang Li, Lai Wei, Yuemin Nan, Zhongping Duan, Enqiang Linghu, Hong You, Huiguo Ding and Jinghang Xu and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Diabetes.

In The Last Decade

Xiaoyuan Xu

108 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)

2023 97 citations Hong You, Fu‐Sheng Wang et al. Journal of Clinical and Translational Hepatology profile →

Peers

Xiaoyuan Xu

EPIDE

HEPAT

MB

SURGE

CB

Carlo Saitta Italy

Rosa Segura Spain

Enver Dolar Türkiye

Keisuke Kakisaka Japan

Mehmet Yücesoy Türkiye

Ömer Özbakır Türkiye

Rakesh Kumar Vasishta India

Aloysious Aravinthan United Kingdom

Andreas Rydning Norway

Carmine Panella Italy

Carlo Saitta Italy

Xiaoyuan Xu

684 ×1.0

EPIDE

582 ×0.9

HEPAT

179 ×1.0

MB

151 ×1.3

SURGE

95 ×0.9

CB

Citations per year, relative to Xiaoyuan Xu Xiaoyuan Xu (= 1×) peers Carlo Saitta

Countries citing papers authored by Xiaoyuan Xu

Since Specialization

Citations

This map shows the geographic impact of Xiaoyuan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoyuan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoyuan Xu more than expected).

Fields of papers citing papers by Xiaoyuan Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoyuan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoyuan Xu. The network helps show where Xiaoyuan Xu may publish in the future.

Co-authorship network of co-authors of Xiaoyuan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoyuan Xu. A scholar is included among the top collaborators of Xiaoyuan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoyuan Xu. Xiaoyuan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Xu, Xiaoyuan, Zhenyu Xie, Huiyong Wang, et al.. (2025). Highly sensitive ratiometric pH nanoprobe based on CuNCs–Rh6G for monitoring intracellular pH and meat freshness. Analytica Chimica Acta. 1377. 344650–344650.

2.

Zhao, Suxian, Jie Li, Lingdi Liu, et al.. (2025). Consensus on the Management of Liver Injury Associated with Targeted Drugs and Immune Checkpoint Inhibitors for Hepatocellular Carcinoma (Version 2024). Journal of Clinical and Translational Hepatology. 0(0). 0–0.

3.

Xu, Xiaoyuan, et al.. (2025). Greenwashing in ESG information disclosure: An intertemporal signaling game approach. International Journal of Production Economics. 287. 109674–109674. 3 indexed citations

4.

Xu, Xiaoyuan, Wengang Li, Ying Han, et al.. (2025). Chinese Guidelines on the Management of Hepatic Encephalopathy in Cirrhosis (2024). Journal of Clinical and Translational Hepatology. 0(0). 0–0. 1 indexed citations

5.

Zeng, Zhan, Yifan Han, Wengang Li, et al.. (2025). Baseline FIB ‐4 May Be a Risk Factor of Recurrence After SBRT in Patients With HBV ‐Related Small HCC. Cancer Medicine. 14(1). e70535–e70535.

6.

Xu, Xiaoyuan, et al.. (2024). Investigation of the morphology and heat transfer characteristics of the frost layer during the early-stage formation with a cellular automata model. International Journal of Heat and Mass Transfer. 228. 125612–125612.

7.

Fan, Jian‐Gao, Xiaoyuan Xu, Yuemin Nan, et al.. (2024). Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024). Journal of Clinical and Translational Hepatology. 0(0). 0–0. 22 indexed citations

8.

You, Hong, Weijia Duan, Shuxiang Li, et al.. (2023). Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021). Journal of Clinical and Translational Hepatology. 0(0). 0–0. 13 indexed citations

9.

Li, Minghui, Xiaojuan Ou, Sujun Zheng, et al.. (2023). Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation. BMC Gastroenterology. 23(1). 224–224. 4 indexed citations

10.

Deng, Yinan, Hong‐Yo Kang, Huiling Xiang, et al.. (2023). [Recompensation of complications in patients with hepatitis B virus-related decompensated cirrhosis treated with entecavir antiviral therapy].. PubMed. 31(7). 692–697.

11.

You, Hong, Fu‐Sheng Wang, Taisheng Li, et al.. (2023). Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022). Journal of Clinical and Translational Hepatology. 0(0). 0–0. 97 indexed citations breakdown →

12.

Xin, Shengliang, et al.. (2022). USP10 Alleviates Palmitic Acid-induced Steatosis through Autophagy in HepG2 Cells. Journal of Clinical and Translational Hepatology. 0(0). 0–0. 9 indexed citations

13.

Tan, Ning, Qian Kang, Ran Cheng, et al.. (2021). Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World Journal of Clinical Cases. 9(21). 5812–5821. 2 indexed citations

14.

Wu, Xiaoning, Jialing Zhou, Wen Xie, et al.. (2019). <p>Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study</p>. Infection and Drug Resistance. Volume 12. 745–757. 8 indexed citations

15.

Tang, Hong, et al.. (2018). Long-Term Outcomes Associated with Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C in China. Value in Health. 21. S65–S65. 3 indexed citations

16.

Shang, Jia, Xiaoyuan Xu, Xinyue Chen, et al.. (2015). Efficacy and related factors of pegylated interferon α-2a plus ribavirin therapy for chronic hepatitis C in non-responders. 8(3). 232–237. 1 indexed citations

17.

Xu, Xiaoyuan, et al.. (2013). Analysis of clinical characteristics between HBeAg-negative and HBeAg-positive patients with chronic hepatitis B. 27(6). 472–473. 1 indexed citations

18.

Jiang, Yufeng, Xiaoyuan Xu, Shanshan Huang, et al.. (2012). GRP78 counteracts cell death and protein aggregation caused by mutant huntingtin proteins. Neuroscience Letters. 516(2). 182–187. 38 indexed citations

19.

Xu, Xiaoyuan, et al.. (2010). Pharmacy Education Quality Assurance in China: Moving Towards a National Accreditation System?. Pharmacy Education. 10(2). 47–49.

20.

Wang, Rengui, Wei Song, Guangfa Wang, et al.. (2003). [Plain radiograph and CT features of 112 patients with SARS in acute stage].. PubMed. 35 Suppl. 29–33. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact